Influence of Granulocyte-Macrophage Colony-Stimulating Factor or Influenza Vaccination on HLA-DR, Infection and Delirium Days in Immunosuppressed Surgical Patients: Double Blind, Randomised Controlled Trial

被引:22
|
作者
Spies, Claudia [1 ,2 ]
Luetz, Alawi [1 ,2 ]
Lachmann, Gunnar [1 ,2 ]
Renius, Markus [1 ,2 ]
von Haefen, Clarissa [1 ,2 ]
Wernecke, Klaus-Dieter [3 ]
Bahra, Marcus [4 ]
Schiemann, Alexander [1 ,2 ]
Paupers, Marco [1 ,2 ]
Meisel, Christian [5 ]
机构
[1] Charite, Campus Charite Mitte, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany
[2] Charite, Campus Virchow Klinikum, D-13353 Berlin, Germany
[3] Sostana GmbH, Berlin, Germany
[4] Charite, Dept Gen Abdominal & Transplantat Surg, Campus Virchow Klinikum, D-13353 Berlin, Germany
[5] Charite, Inst Med Immunol, Campus Virchow Klinikum, D-13353 Berlin, Germany
来源
PLOS ONE | 2015年 / 10卷 / 12期
关键词
FACTOR GM-CSF; INTENSIVE-CARE; SYSTEMIC INFLAMMATION; 3; SCORES; EXPRESSION; MORTALITY; VACCINES; SEPSIS; SAFETY; PATHOPHYSIOLOGY;
D O I
10.1371/journal.pone.0144003
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose Surgical patients are at high risk for developing infectious complications and postoperative delirium. Prolonged infections and delirium result in worse outcome. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and influenza vaccination are known to increase HLA-DR on monocytes and improve immune reactivity. This study aimed to investigate whether GM-CSF or vaccination reverses monocyte deactivation. Secondary aims were whether it decreases infection and delirium days after esophageal or pancreatic resection over time. Methods In this prospective, randomized, placebo-controlled, double-blind, double dummy trial setting on an interdisciplinary ICU of a university hospital 61 patients with immunosuppression (monocytic HLA-DR [mHLA-DR] < 10,000 monoclonal antibodies [mAb] per cell) on the first day after esophageal or pancreatic resection were treated with either GM-CSF (250 mu g/m2/d), influenza vaccination (Mutagrip 0.5 ml/d) or placebo for a maximum of 3 consecutive days if mHLA-DR remained below 10,000 mAb per cell. HLA-DR on monocytes was measured daily until day 5 after surgery. Infections and delirium were followed up for 9 days after surgery. Primary outcome was HLA-DR on monocytes, and secondary outcomes were duration of infection and delirium. Results mHLA-DR was significantly increased compared to placebo (p < 0.001) and influenza vaccination (p < 0.001) on the second postoperative day. Compared with placebo, GM-CSF-treated patients revealed shorter duration of infection (p < 0.001); the duration of delirium was increased after vaccination (p = 0.003). Conclusion Treatment with GM-CSF in patients with postoperative immune suppression was safe and effective in restoring monocytic immune competence. Furthermore, therapy with GM-CSF reduced duration of infection in immune compromised patients. However, influenza vaccination increased duration of delirium after major surgery.
引用
收藏
页数:15
相关论文
共 12 条
  • [1] The BlastGen study: a randomized controlled trial of blastocyst media supplemented with granulocyte-macrophage colony-stimulating factor
    Rose, Ryan D.
    Barry, Michael F.
    Dunstan, Emma, V
    Yuen, Siu Man
    Cameron, Lyndal P.
    Knight, Emma J.
    Norman, Robert J.
    Hull, M. Louise
    REPRODUCTIVE BIOMEDICINE ONLINE, 2020, 40 (05) : 645 - 652
  • [2] Granulocyte-Macrophage Colony-stimulating Factor to Reverse Sepsis-associated Immunosuppression A Double-Blind, Randomized, Placebo-controlled Multicenter Trial
    Meisel, Christian
    Schefold, Joerg C.
    Pschowski, Rene
    Baumann, Tycho
    Hetzger, Katrin
    Gregor, Jan
    Weber-Carstens, Steffen
    Hasper, Dietrich
    Keh, Didier
    Zuckermann, Heidrun
    Reinke, Petra
    Volk, Hans-Dieter
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 180 (07) : 640 - 648
  • [3] Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: The GRID randomized controlled trial
    Vacheron, Charles-Herve
    Lepape, Alain
    Venet, Fabienne
    Monneret, Guillaume
    Gueyffier, Francois
    Boutitie, Florent
    Vallin, Helene
    Schwebel, Carole
    Maucort-Boulch, Delphine
    Friggeri, Arnaud
    JOURNAL OF CRITICAL CARE, 2023, 78
  • [4] A randomized, controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newborns less than 32 weeks gestation
    Carr, R
    Modi, N
    Doré, CJ
    El-Rifai, R
    Lindo, D
    PEDIATRICS, 1999, 103 (04) : 796 - 802
  • [5] Intraperitoneal administration of fosfomycin, metronidazole, and granulocyte-macrophage colony-stimulating factor in patients undergoing appendectomy is safe: a phase II clinical trial
    Fonnes, Siv
    Holzknecht, Barbara Juliane
    Arpi, Magnus
    Rosenberg, Jacob
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [6] Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
    Senzer, Neil N.
    Kaufman, Howard L.
    Amatruda, Thomas
    Nemunaitis, Mike
    Reid, Tony
    Daniels, Gregory
    Gonzalez, Rene
    Glaspy, John
    Whitman, Eric
    Harrington, Kevin
    Goldsweig, Howard
    Marshall, Tracey
    Love, Colin
    Coffin, Robert
    Nemunaitis, John J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5763 - 5771
  • [7] Safety of granulocyte colony-stimulating factor (filgrastim) in intubated patients in the intensive care unit:: Interim analysis of a prospective, placebo-controlled, double-blind study
    Pettilä, V
    Takkunen, O
    Varpula, T
    Markkola, A
    Porkka, K
    Valtonen, V
    CRITICAL CARE MEDICINE, 2000, 28 (11) : 3620 - 3625
  • [8] The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial
    Hoffman, Karen E.
    Pugh, Stephanie L.
    James, Jennifer L.
    Scarantino, Charles
    Movsas, Benjamin
    Valicenti, Richard K.
    Fortin, Andre
    Pollock, JonDavid
    Kim, Harold
    Brachman, David G.
    Berk, Lawrence B.
    Bruner, Deborah Watkins
    Kachnic, Lisa A.
    QUALITY OF LIFE RESEARCH, 2014, 23 (06) : 1841 - 1858
  • [9] Lack of beneficial effects of granulocyte colony-stimulating factor in patients with subacute myocardial infarction undergoing late revascularization: a double-blind, randomized, placebo-controlled clinical trial
    Karimabad, Hossein Mehdikhani
    Shabestari, Mahmood
    Baharvand, Hossein
    Vosough, Ahmad
    Gourabi, Hamid
    Shahverdi, Abdolhossein
    Shamsian, Aliakbar
    Abdolhoseini, Saeid
    Moazzami, Kasra
    Marjanimehr, Mehdi Moradi
    Emami, Farhad
    Bidkhori, Hamid Reza
    Hamedanchi, Ali
    Talebi, Soheila
    Farrokhi, Farid
    Jabbari-Azad, Farhad
    Fadavi, Mahsa
    Garivani, Uousef
    Mahmoodi, Mahmood
    Aghdami, Nasser
    ACTA CARDIOLOGICA, 2011, 66 (02) : 219 - 224
  • [10] Subcutaneous granulocyte colony-stimulating factor administration for subacute traumatic spinal cord injuries, report of neurological and functional outcomes: a double-blind randomized controlled clinical trial
    Derakhshanrad, Nazi
    Saberi, Hooshang
    Yekaninejad, Mir Saeed
    Joghataei, Mohammad Taghi
    JOURNAL OF NEUROSURGERY-SPINE, 2019, 30 (01) : 19 - 30